{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06395506",
            "orgStudyIdInfo": {
                "id": "23-0215"
            },
            "organization": {
                "fullName": "The University of Texas Medical Branch, Galveston",
                "class": "OTHER"
            },
            "briefTitle": "THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation",
            "officialTitle": "An Open-label Randomized Trial of Exercise \u00b1 Creatine Supplementation to Augment the Adaptations of Exercise Training in Cancer Survivors",
            "acronym": "THRIVE",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "thrive-well-cancer-fdtn-supplementation"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-05-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-05-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-19",
            "studyFirstSubmitQcDate": "2024-04-29",
            "studyFirstPostDateStruct": {
                "date": "2024-05-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "The University of Texas Medical Branch, Galveston",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "ThriveWell Cancer Foundation",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study's purpose is to evaluate whether creatine supplementation can help breast cancer survivors respond quicker to exercise by improving strength, endurance, and body composition. We are seeking to compare information collected from healthy woman of the same age who have never had breast cancer to those participants who have had breast cancer and undergone chemotherapy treatment.",
            "detailedDescription": "The primary objective of this study is to determine the effects of creatine supplementation in modulating strength and physical function in breast cancer survivors that have recently completed chemotherapy. The primary objective is to determine the effects of creatine in modulating strength and physical function in cancer survivors."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Breast Cancer Female",
                "Muscle Weakness"
            ],
            "keywords": [
                "Breast Cancer",
                "Breast Cancer Female",
                "Exercise",
                "Creatine Supplement"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "This study plans to enroll 30 breast cancer patients who have completed chemotherapy within 6 months prior to consenting for this study. Each arm will have 15 participants. One arm will receive creatine and the other will serve as the control group with no creatine.",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Age-Matched Control Group",
                    "type": "NO_INTERVENTION",
                    "description": "Women who have never been diagnosed with cancer."
                },
                {
                    "label": "Creatine Supplement Group",
                    "type": "EXPERIMENTAL",
                    "description": "Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol. Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.",
                    "interventionNames": [
                        "Dietary Supplement: Creatine"
                    ]
                },
                {
                    "label": "Non-Creatine Supplement Group",
                    "type": "NO_INTERVENTION",
                    "description": "Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a Fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study."
                }
            ],
            "interventions": [
                {
                    "type": "DIETARY_SUPPLEMENT",
                    "name": "Creatine",
                    "description": "Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.",
                    "armGroupLabels": [
                        "Creatine Supplement Group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in strength in breast cancer survivors",
                    "description": "Determine the change in strength in breast cancer survivors by comparing pre and post measurements of strength measurement tools including 1RM/10RM/Biodex evaluations.",
                    "timeFrame": "baseline and 12 weeks"
                },
                {
                    "measure": "Change in physical functional capacity in breast cancer survivors",
                    "description": "Determine the change in strength in breast cancer survivors by comparing pre and post measurements of the six minute walk test.",
                    "timeFrame": "baseline and 12 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change intramuscular storage of creatine",
                    "description": "Determine the change in intramuscular storage of creatine by comparing pre and post vastus lateralis muscle using MRI.",
                    "timeFrame": "baseline and 12 weeks"
                },
                {
                    "measure": "Change in body composition in cancer survivors",
                    "description": "Determine the change in body composition in breast cancer survivors by pre and post measurements of bone mass as well as lean vs fat mass via a DEXA scan.",
                    "timeFrame": "baseline and 12 weeks"
                },
                {
                    "measure": "Change in the return of strength for breast cancer survivors with creatine + exercise",
                    "description": "Breast cancer survivors who complete 12-weeks of exercise with creatine supplementation group who regained strength and physical function to that of women of similar age who never had cancer.",
                    "timeFrame": "12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria (Breast Cancer Group)\n\n* Age 18-75 years of age\n* Diagnosis of breast cancer requiring chemotherapy\n* Recent (within 6 months) completion of chemotherapy\n* Willing to attend 3 virtual-based exercise sessions per week\n* Able to take oral medications\n* Participant is willing and able to provide consent to participating in the study\n* Serum creatinine \u2264 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \u226530 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation.\n\nExclusion criteria (Breast Cancer Group)\n\n* Physical indications where performing exercise may be limited and/or contraindicated\n* Poorly controlled hypertension (blood pressure \\> 160/95mmHg)\n* Current tobacco use (within 6 months)\n* Anabolic steroids use\n* Pitting edema greater than 2+\n* Currently undergoing chemotherapy treatment for cancer\n* History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation)\n* Pregnant or plan to become pregnant during the study\n* Recent (within one month) or anticipated treatment with corticosteroids (except for short term use during the time of chemotherapy), or other appetite stimulants\n* Serum creatinine \\> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \\< 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation\n* Currently taking creatine supplements\n* Lack of availability to a smartphone and/or internet\n\nInclusion Criteria (Healthy Age-matched Control Group)\n\n* Age 18-75 years of age\n* Have never been diagnosed with cancer\n* Willing to provide consent to participate in this study\n\nExclusion Criteria (Healthy Age-matched Control Group)\n\n* Physical indications where performing exercise may be limited and/or contraindicated\n* Poorly controlled hypertension (blood pressure \\> 160/95mmHg)\n* Current tobacco use (within 6 months)\n* Anabolic steroids use\n* Pitting edema greater than 2+\n* History of cancer diagnosis\n* History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation)\n* Pregnant or currently taking prescribed medication to prepare for pregnancy (i.e.\n\nhormonal therapy for IVF)\n\n* Recent (within one month) treatment with corticosteroids\n* Recent (within one month) use of appetite stimulants or appetite suppressants\n* Serum creatinine \\> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \\< 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation\n* Diagnosed Bipolar Disorder or MDQ score indicative of bipolar disorder or Neurological disorders\n* Uncontrolled diabetes (A1c of 6.5% or higher)\n* Currently taking creatine supplements\n* Lack of availability to a smartphone and/or internet",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lisa Thibodeaux, RN,BSN",
                    "role": "CONTACT",
                    "phone": "4094741756",
                    "email": "lbthibod@utmb.edu"
                },
                {
                    "name": "Rebecca Geck, MPH,APRN,CPT",
                    "role": "CONTACT",
                    "phone": "4092660496",
                    "email": "raschaef@utmb.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Darpan Patel, PhD",
                    "affiliation": "University of Texas",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The University of Texas Medical Branch, Galveston",
                    "city": "Galveston",
                    "state": "Texas",
                    "zip": "77555",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lisa Thibodeaux, RN,BSN",
                            "role": "CONTACT",
                            "phone": "409-474-1756",
                            "email": "lbthibod@utmb.edu"
                        },
                        {
                            "name": "Rebecca Geck, MPH,APRN,CPT",
                            "role": "CONTACT",
                            "phone": "4092660496",
                            "email": "raschaef@utmb.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.30135,
                        "lon": -94.7977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000018908",
                    "term": "Muscle Weakness"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000020879",
                    "term": "Neuromuscular Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20944",
                    "name": "Muscle Weakness",
                    "asFound": "Muscle Weakness",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13204",
                    "name": "Paresis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4554",
                    "name": "Asthenia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22619",
                    "name": "Neuromuscular Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M12478",
                    "name": "Nicotine",
                    "relevance": "LOW"
                },
                {
                    "id": "T385",
                    "name": "Creatine",
                    "asFound": "Cardiovascular Risk",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Ot",
                    "name": "Other Dietary Supplements"
                }
            ]
        }
    },
    "hasResults": false
}